Wound Mgmt Tech (WNDM) 0.1199 $WNDM
Wound Management Technologies Growth Continues with Record Sales for First Quarter 2014 Following a Strong 2013 Year End
ACCESSWIRE - Tue Apr 22, 10:24AM CDT
ADDISON, TX / ACCESSWIRE / April 22, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM) announced revenues of nearly $700,000 for the first quarter of 2014, a gain of 82% over the first quarter of 2013. Approximately 80% of revenues were from the CellerateRX(R) product line and the other 20% of revenue occurred in the Resorbable Orthopedic Products, LLC subsidiary (ROP). The CellerateRX first quarter revenues included sales to 65 new accounts mixed between the wound care and surgical product lines. "Our growth mirrors the results we anticipated in our three year strategic plan and we are excited about the organic growth that is occurring," stated Robert Lutz, Jr., Chairman and CEO. "This is the strongest quarter ever for CellerateRX sales. ROP's revenues were from license fees and now we will begin collecting royalty income from this license. Our team is collectively doing a great job of meeting our goals."
Wound Management Technologies Announces Jane Fore, MD as Chief Medical Officer and Dr. Alec Hochstein as Medical Director
ACCESSWIRE - Wed Mar 19, 8:41AM CDT
ADDISON, TX / ACCESSWIRE / March 19, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM), announced today that Dr. Jane Fore is the new Chief Medical Officer for the Wound Care Innovations Subsidiary and Dr. Alec Hochstein has joined the company as Medical Director. Both are actively involved in the CellerateRX(R) Activated Collagen product line.
Wound Management Technologies Adds CFO and Director of Research and Development
ACCESSWIRE - Mon Mar 17, 3:11PM CDT
ADDISON, TX / ACCESSWIRE / March 17, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM) has engaged Mr. Darren Stine as the Company's new Chief Financial Officer and Mr. Barry Constantine has agreed to expand his role within the Company as its new Director of Research and Development.
Wound Managements' Subsidiary, Resorbable Orthopedic Products, Announces BioStructures has FDA 510(k) Clearance for Innovative Bioactive Bone Graft Putty and Bone Graft Extender; Commercial License Granted
ACCESSWIRE - Tue Feb 18, 7:36AM CST
ADDISON, TX - (ACCESSWIRE - February 18, 2014) - Wound Management Technologies, Inc., (OTCQB: WNDM) announced today that its subsidiary, Resorbable Orthopedic Products, LLC, has granted a commercial license to BioStructures, LLC to market their newly FDA 510(k) cleared Bioactive Bone Graft Putty (Signafuse™). BioStructures developed this product under the Development and License Agreement with ROP that was announced on November 11, 2011 under which BioStructures combined their proprietary biomaterials with ROP's patented resorbable wax carrier. This license creates Resorbable Orthopedic Products first revenue stream.
Wound Management Technologies Inc. Receives Financing from Key Shareholder Group; Turns Focus to Strategic Growth
ACCESSWIRE - Wed Dec 18, 8:17AM CST
ADDISON, TX - (Accesswire - December 18, 2013) - Wound Management Technologies, Inc., (OTCQB: WNDM) announced today that it has received a financing commitment from existing shareholders to invest an additional $2.4 million in Series C preferred shares and to convert over $1.5 M of existing debt to the Series C preferred shares. The financing subscription documents have been received and the commitment will be fully funded by February 28, 2014. The Board of Directors unanimously supported this action and authorized a $3 M extension to the Series C offering.
Wound Management Technologies and Brookhaven Medical Agree to Explore Business Relationships, not a Merger
ACCESSWIRE - Fri Dec 13, 1:14PM CST
Addison, TX - (ACCESSWIRE- December 13, 2013) Wound Management Technologies Inc. (OTCQB:WNDM) and Brookhaven Medical, Inc. announced today that they have mutually agreed not to proceed with a previously announced merger. Both companies and their boards have determined it to be in the best interests of their companies and stockholders respectively not to enter into a definitive merger agreement.
2013 Report on the International Collagen and HA-Based Biomaterials Market
M2 - Mon Dec 02, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/dbnhsw/collagen_and#summary) has announced the addition of the "2013 Report on the International Collagen and HA-Based Biomaterials Market" report to their offering. Biomaterials are of vital importance in the medical device industry, both for the discovery and development of synthetic organs, aesthetic procedures, and personal healthcare products. Growth in the biomaterials market continues to be fueled by heightened interest in personal healthcare and growing size of aging population. The dynamic and diverse market for biomaterials, comprising collagen and hyaluronic acid-based (HA-based) products, is led by the US market, as stated by the new market research report on Collagen and HA-based Biomaterials market. The US is followed by Europe and Japan. Key growth drivers of the collagen and hyaluronic acid-based products include increasing prevalence of diseases, including osteoarthritis, along with a greater importance on fitness and health in old age. Other drivers include development of new products with wide application areas; introduction of single-injection visco supplement products for osteoarthritis patients; strong growth in the under-penetrated developing markets, including the Asia-Pacific region; new vistas in implantable devices, tissue engineering, bone grafting substance, and facial aesthetic dermal fillers. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Global Market Overview 2. Market Trends And Issues 3. Biomaterials - A Brief Overview 4. Segment Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Corporate Activity In The Recent Past - A Perspective Builder 8. Focus On Select Key Players 9. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 63 (including Divisions/Subsidiaries - 69) - The United States (44) - Canada (2) - Japan (3) - Europe (18) - France (1) - Germany (3) - The United Kingdom (5) - Italy (1) - Rest of Europe (
- Asia-Pacific (Excluding Japan) (1) - Middle-East (1) Companies Mentioned: - Abbott Laboratories - Bausch & Lomb - Collagen Matrix - DePuy Mitek - Fibrocell Science - Galderma - Integra Lifesciences - Johnson & Johnson - Kinetic Concepts - Medtronic - Novozymes Biopharma - Oasis Medical - Q-Med - Smith & Nephew - TiGenix - Wound Management Technologies - Zimmer For more information visit http://www.researchandmarkets.com/research/db...nd#summary
CellerateRX(R) Reports Significant Second Quarter and Annual Sales Increase
Marketwire - Mon Aug 26, 8:47AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM) announces an increase in sales of CellerateRX(R) for the second quarter, ending June 2013 up 54% over the same period in 2012. Sales year to date have risen 111% over year to date sales in 2012. Robert Lutz Jr., chief executive officer, commented, "We attribute our growing success to increased use of CellerateRx for surgical wounds in hospitals and increased use in the woundcare marketplace." Lutz added, "We will continue to expand our sales and distribution efforts with hospitals, woundcare centers, and the longterm care and hospice market places adding new accounts based on the strong efficacy of the product."
Wound Management Technologies Enters Into Distribution Agreement With Academy Medical
Marketwire - Mon Jul 08, 3:30PM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM) announced it has entered into a distribution agreement with Academy Medical, LLC, a veteran-owned distributor of medical products, to sell its CellerateRX line of products to the VA facilities across the country. The Veterans Administration system represents over 168 Hospitals, 1700 "sites of care" facilities and 8.3 million veterans. The agreement has a term of five years and minimum purchase amounts from Wound Management of $600,000 and 1.5 million the first two years growing to $3 million by year five of the contract.
Wound Management Technologies 2012 Sales Strategy Shows Positive Results; Receives Final Resolution with SEC
PR Newswire - Tue Feb 05, 9:30AM CST
WOUND MANAGEMENT TECHNOLOGIES (OTCQB: WNDM | WNDM.PK) finished 2012 with fourth quarter customer sales revenues of approximately $440,000 (an increase of 23% over the previous quarter) and annual sales revenues of approximately $1.18M. In May of 2012 the Company announced it had completed a new three-year strategic plan that focuses on CellerateRX® customer sales and that a new surgical product would be introduced in 2012. In October 2012 the Company announced positive results for the new CellerateRX® surgical products. "Clearly our plan and our team's efforts are yielding results," stated Robert H. Lutz, Jr., Chairman and CEO of the company. "We expect the upward sales trend to continue throughout 2013 and beyond."
Wound Management Technologies Growth Continues with Record Sales for First Quarter 2014 Following a Strong 2013 Year End
ACCESSWIRE - Tue Apr 22, 10:24AM CDT
ADDISON, TX / ACCESSWIRE / April 22, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM) announced revenues of nearly $700,000 for the first quarter of 2014, a gain of 82% over the first quarter of 2013. Approximately 80% of revenues were from the CellerateRX(R) product line and the other 20% of revenue occurred in the Resorbable Orthopedic Products, LLC subsidiary (ROP). The CellerateRX first quarter revenues included sales to 65 new accounts mixed between the wound care and surgical product lines. "Our growth mirrors the results we anticipated in our three year strategic plan and we are excited about the organic growth that is occurring," stated Robert Lutz, Jr., Chairman and CEO. "This is the strongest quarter ever for CellerateRX sales. ROP's revenues were from license fees and now we will begin collecting royalty income from this license. Our team is collectively doing a great job of meeting our goals."
Wound Management Technologies Announces Jane Fore, MD as Chief Medical Officer and Dr. Alec Hochstein as Medical Director
ACCESSWIRE - Wed Mar 19, 8:41AM CDT
ADDISON, TX / ACCESSWIRE / March 19, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM), announced today that Dr. Jane Fore is the new Chief Medical Officer for the Wound Care Innovations Subsidiary and Dr. Alec Hochstein has joined the company as Medical Director. Both are actively involved in the CellerateRX(R) Activated Collagen product line.
Wound Management Technologies Adds CFO and Director of Research and Development
ACCESSWIRE - Mon Mar 17, 3:11PM CDT
ADDISON, TX / ACCESSWIRE / March 17, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM) has engaged Mr. Darren Stine as the Company's new Chief Financial Officer and Mr. Barry Constantine has agreed to expand his role within the Company as its new Director of Research and Development.
Wound Managements' Subsidiary, Resorbable Orthopedic Products, Announces BioStructures has FDA 510(k) Clearance for Innovative Bioactive Bone Graft Putty and Bone Graft Extender; Commercial License Granted
ACCESSWIRE - Tue Feb 18, 7:36AM CST
ADDISON, TX - (ACCESSWIRE - February 18, 2014) - Wound Management Technologies, Inc., (OTCQB: WNDM) announced today that its subsidiary, Resorbable Orthopedic Products, LLC, has granted a commercial license to BioStructures, LLC to market their newly FDA 510(k) cleared Bioactive Bone Graft Putty (Signafuse™). BioStructures developed this product under the Development and License Agreement with ROP that was announced on November 11, 2011 under which BioStructures combined their proprietary biomaterials with ROP's patented resorbable wax carrier. This license creates Resorbable Orthopedic Products first revenue stream.
Wound Management Technologies Inc. Receives Financing from Key Shareholder Group; Turns Focus to Strategic Growth
ACCESSWIRE - Wed Dec 18, 8:17AM CST
ADDISON, TX - (Accesswire - December 18, 2013) - Wound Management Technologies, Inc., (OTCQB: WNDM) announced today that it has received a financing commitment from existing shareholders to invest an additional $2.4 million in Series C preferred shares and to convert over $1.5 M of existing debt to the Series C preferred shares. The financing subscription documents have been received and the commitment will be fully funded by February 28, 2014. The Board of Directors unanimously supported this action and authorized a $3 M extension to the Series C offering.
Wound Management Technologies and Brookhaven Medical Agree to Explore Business Relationships, not a Merger
ACCESSWIRE - Fri Dec 13, 1:14PM CST
Addison, TX - (ACCESSWIRE- December 13, 2013) Wound Management Technologies Inc. (OTCQB:WNDM) and Brookhaven Medical, Inc. announced today that they have mutually agreed not to proceed with a previously announced merger. Both companies and their boards have determined it to be in the best interests of their companies and stockholders respectively not to enter into a definitive merger agreement.
2013 Report on the International Collagen and HA-Based Biomaterials Market
M2 - Mon Dec 02, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/dbnhsw/collagen_and#summary) has announced the addition of the "2013 Report on the International Collagen and HA-Based Biomaterials Market" report to their offering. Biomaterials are of vital importance in the medical device industry, both for the discovery and development of synthetic organs, aesthetic procedures, and personal healthcare products. Growth in the biomaterials market continues to be fueled by heightened interest in personal healthcare and growing size of aging population. The dynamic and diverse market for biomaterials, comprising collagen and hyaluronic acid-based (HA-based) products, is led by the US market, as stated by the new market research report on Collagen and HA-based Biomaterials market. The US is followed by Europe and Japan. Key growth drivers of the collagen and hyaluronic acid-based products include increasing prevalence of diseases, including osteoarthritis, along with a greater importance on fitness and health in old age. Other drivers include development of new products with wide application areas; introduction of single-injection visco supplement products for osteoarthritis patients; strong growth in the under-penetrated developing markets, including the Asia-Pacific region; new vistas in implantable devices, tissue engineering, bone grafting substance, and facial aesthetic dermal fillers. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Global Market Overview 2. Market Trends And Issues 3. Biomaterials - A Brief Overview 4. Segment Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Corporate Activity In The Recent Past - A Perspective Builder 8. Focus On Select Key Players 9. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 63 (including Divisions/Subsidiaries - 69) - The United States (44) - Canada (2) - Japan (3) - Europe (18) - France (1) - Germany (3) - The United Kingdom (5) - Italy (1) - Rest of Europe (
- Asia-Pacific (Excluding Japan) (1) - Middle-East (1) Companies Mentioned: - Abbott Laboratories - Bausch & Lomb - Collagen Matrix - DePuy Mitek - Fibrocell Science - Galderma - Integra Lifesciences - Johnson & Johnson - Kinetic Concepts - Medtronic - Novozymes Biopharma - Oasis Medical - Q-Med - Smith & Nephew - TiGenix - Wound Management Technologies - Zimmer For more information visit http://www.researchandmarkets.com/research/db...nd#summary CellerateRX(R) Reports Significant Second Quarter and Annual Sales Increase
Marketwire - Mon Aug 26, 8:47AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM) announces an increase in sales of CellerateRX(R) for the second quarter, ending June 2013 up 54% over the same period in 2012. Sales year to date have risen 111% over year to date sales in 2012. Robert Lutz Jr., chief executive officer, commented, "We attribute our growing success to increased use of CellerateRx for surgical wounds in hospitals and increased use in the woundcare marketplace." Lutz added, "We will continue to expand our sales and distribution efforts with hospitals, woundcare centers, and the longterm care and hospice market places adding new accounts based on the strong efficacy of the product."
Wound Management Technologies Enters Into Distribution Agreement With Academy Medical
Marketwire - Mon Jul 08, 3:30PM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM) announced it has entered into a distribution agreement with Academy Medical, LLC, a veteran-owned distributor of medical products, to sell its CellerateRX line of products to the VA facilities across the country. The Veterans Administration system represents over 168 Hospitals, 1700 "sites of care" facilities and 8.3 million veterans. The agreement has a term of five years and minimum purchase amounts from Wound Management of $600,000 and 1.5 million the first two years growing to $3 million by year five of the contract.
Wound Management Technologies 2012 Sales Strategy Shows Positive Results; Receives Final Resolution with SEC
PR Newswire - Tue Feb 05, 9:30AM CST
WOUND MANAGEMENT TECHNOLOGIES (OTCQB: WNDM | WNDM.PK) finished 2012 with fourth quarter customer sales revenues of approximately $440,000 (an increase of 23% over the previous quarter) and annual sales revenues of approximately $1.18M. In May of 2012 the Company announced it had completed a new three-year strategic plan that focuses on CellerateRX® customer sales and that a new surgical product would be introduced in 2012. In October 2012 the Company announced positive results for the new CellerateRX® surgical products. "Clearly our plan and our team's efforts are yielding results," stated Robert H. Lutz, Jr., Chairman and CEO of the company. "We expect the upward sales trend to continue throughout 2013 and beyond."
